Trials / Completed
CompletedNCT00124332
STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)
Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSounds), in Overweight Patients With Clustering Risk Factors
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 839 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered on top of standard behavioral and pharmacological therapy given as needed, in patients with abdominal obesity associated with current smoking and/or metabolic syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimonabant (SR141716) | |
| DRUG | Placebo |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2005-07-27
- Last updated
- 2009-04-20
Locations
9 sites across 9 countries: United States, Australia, Belgium, Canada, France, Italy, Netherlands, Poland, Spain
Source: ClinicalTrials.gov record NCT00124332. Inclusion in this directory is not an endorsement.